Summary
A total of 32 patients with advanced squamous-cell carcinoma of the cervix were treated with 300 mg/m2 i. v. carboplatin and 5 g/m2 ifosfamide as a 24-h i. v. infusion, both given on day 1 every 4 weeks. In all, 3 (9%) complete responses (CRs) and 19 (59%) objective responses (CR+PR) were achieved in 32 patients. Myelosuppression with leukopenia and/or thrombocytopenia of WHO grade 4 in 28% and 13% of patients, respectively, was the main toxicity. The results of our study suggest that carboplatin/ifosfamide is active as neoadjuvant treatment in advanced cervical cancer.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Bonomi P, Blessing JA, Stehman FB, DiSaia PJ, Walton L, Major FJ (1985) Randomized trial of three cisplatin dose schedules in squamous-cell carcinoma of the cervix: a Gynecologic Oncology Group study. J Clin Oncol 3:1079
Buxton EJ, Meanwell CA, Hilton C, Mould JJ, Spooner D, Chetiyawardana A, Latief T, Paterson M, Redmann CW, Luesley DM, Blackledge GR (1989) Combination bleomycin, ifosfamide and cisplatin chemotherapy in cervical cancer. J Natl Cancer Inst 81:359
Coleman RE, Harper PG, Gallagher C, Osborne R, Rankin EM, Silverstone AC, Slevin ML, Souhami RL, Tobias JS, Trask CW, Wiltshaw E (1986) A phase-II study of ifosfamide in advanced and relapsed carcinoma of the cervix. Cancer Chemother Pharmacol 18: 280
Coleman RE, Clarke J, Slevin ML, Wiltshaw E, Harper PG (1988) Ifosfamide (I) and ifosfamide+cisplatin (P) chemotherapy for advanced cervical carcinoma. Br J Cancer 58:273
Dinh TV, Dillard EA, Doherty MG (1989) Ifosfamide in cervical cancer: early phase-II results in patients with advanced or recurrent disease (Abstr. 617). Proc Am Soc Clin Oncol 8:158
FIGO (1988) Report on the results of treatment in gynecological cancer, vol 20, FIGO
Forastiere AA, Schnur GA (1984) Cervical cancer: role of chemotherapy. In: Forastiere AA (ed) Gynecologic cancer. Churchill Livingstone. New York Edinburgh London Melbourne, p 93
Lira-Puerto V, Silva A, Groshen S, Martinez R, Morris M, Morales-Canfield F, Tenoric F, Muggia F (1989) Carboplatin (CBDCA) or CHIP: final report of the 3rd phase-II NCI-PAHO study in advanced cervical cancer. Proc Am Soc Clin Oncol 8:A622
McGuire WP, Arseneau JC, Blessing JA, Given FT, Hatch KD, Creasman WT, DiSaia PJ, Teng NN (1988) Randomized comparison of carboplatin (CP) and iproplatin (IP) in advanced squamous carcinoma of the uterine cervix (SCUC): a Gynecologic Oncology Group (GOG) study. Proc Am Soc Clin Oncol 7:A521
Meanwell CA, Mould JJ, Blackledge G, Lawton FG, Stuart NSA, Kavanagh J, Latief TN, Spooner D, Chetiyawardana AD (1986) Phase II study of ifosfamide in cervical cancer. Cancer Treat Rep 70: 727
Miller AB (1981) Reporting results of cancer treatment. Cancer 47: 207
Rozenzcweig M, Martin A, Beltangady M, Goodlow J, Bragmann K, Wiltshaw E, Mangioni C, Adams M, Canetta R (1989) Comparison of carboplatin and cisplatin given as first line single agent chemotherapy for stage III/IV ovarian cancer: a metaanalysis of three randomized trials. In: Proceedings, Carboplatin Workshop Program and Abstracts, San Francisco
Symonds RP, Burnett RA, Habeshaw T, Kaye SB, Snee MP, Watson ER (1989) The prognostic value of a response to chemotherapy given before radiotherapy in advanced cancer of cervix. Br J Cancer 59: 473
Thigpen JT, Blessing JA, DiSaia PJ, Fowler WC Jr, Hatch KD (1989) A randomized comparison of a rapid versus prolonged (24 h) infusion of cisplatin in therapy of squamous cell carcinoma of the uterine cervix: a Gynecologic Oncology Group study. Gynecol Oncol 32:198
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Kühnle, H., Meerpohl, H.G., Eiermann, W. et al. Phase II study of carboplatin/ifosfamide in untreated advanced cervical cancer. Cancer Chemother. Pharmacol. 26 (Suppl 1), S33–S35 (1990). https://doi.org/10.1007/BF00685414
Issue Date:
DOI: https://doi.org/10.1007/BF00685414